Looking beyond a few hard cut-offs in assessing ADMET Risk™

Authors: Clark RD
Software: ADMET Predictor®
Division: PBPK

Abstract

Drug discovery and development is a multi-objective problem. Unfortunately, it is easy to focus exclusively on in vitro activity against the therapeutic target and not consider absorption, distribution, metabolism, excretion, and toxicity (ADMET) until late in a development programme. The predictable result is late-stage failures.

By Robert D Clark